002390！信邦制药被提起公诉，股民或可证券维权

Core Viewpoint - Guizhou Xinbang Pharmaceutical Co., Ltd. is facing legal action for alleged corporate bribery, which has raised concerns about the company's timely disclosure of this significant event [1][2][3] Group 1: Legal Proceedings - The company received an indictment from the People's Procuratorate of Kaiyang County, Guizhou, regarding allegations of corporate bribery [1][2] - The indictment has led to discussions in the market about whether the company adequately disclosed this major event [1][2] Group 2: Investor Compensation - A compensation team has announced that affected investors can voluntarily register for claims through the "Sina Investor Rights Protection Platform" [2][3] - Investors eligible for compensation must have purchased shares before December 11, 2025, and held them regardless of whether they sold after that date [2][3] - The specific compensation range will be determined by the court [2][3] Group 3: Market Reaction - Following the announcement of the indictment, the company's stock price experienced a significant drop, hitting the daily limit down [1]